Related Experiment Videos
K-ras mutations and RASSF1A promoter methylation in colorectal cancer
Manon van Engeland1, Guido M J M Roemen, Mirian Brink
1Department of Pathology, University Maastricht, P.O. Box 616 6200 MD Maastricht, The Netherlands.
Abstract:
Human cancer is characterized by genetic and epigenetic alterations. In this study we provide evidence for the interruption of Ras signaling in sporadic colorectal cancer (CRC) by either genetic activation of the K-ras oncogene or epigenetic silencing of the putative tumor suppressor gene RASSF1A. Paraffin embedded tumor tissue samples from 222 sporadic CRC patients were analysed for K-ras codon 12 and codon 13 activating mutations and RASSF1A promoter hypermethylation. Overall, K-ras mutations were observed in 87 of 222 (39%) and RASSF1A methylation was observed in 45 of 222 (20%) of CRCs. Mutation of K-ras alone was detected in 76 of 222 (34%) CRCs. RASSF1A promoter methylation with wild-type K-ras was observed in 34 of 222 (15%) CRCs. In 101 of 222 (46%) CRCs neither K-ras mutations nor RASSF1A methylation was observed and 11 of 222 (5%) CRCs showed both K-ras mutations and RASSF1A methylation. These data show that the majority of the studied CRCs with K-ras mutations lack RASSF1A promoter methylation, an event which occurs predominantly in K-ras wild-type CRCs (P=0.023, Chi-square test).
Insights
Ras signaling disruptions in colorectal cancer (CRC) involve K-ras mutations or RASSF1A silencing. K-ras mutations were common, while RASSF1A methylation occurred mainly in K-ras wild-type tumors, suggesting distinct pathways in CRC development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Human cancers, including colorectal cancer (CRC), exhibit genetic and epigenetic alterations.
- Ras signaling pathway plays a crucial role in cell growth and is frequently disrupted in various cancers.
- Aberrant K-ras oncogene activation and epigenetic silencing of tumor suppressor genes like RASSF1A are implicated in cancer development.
Purpose of the Study:
- To investigate the interplay between K-ras oncogene mutations and RASSF1A promoter hypermethylation in sporadic colorectal cancer (CRC).
- To determine the frequency of these alterations and their co-occurrence in CRC patient samples.
Main Methods:
- Analysis of paraffin-embedded tumor tissue samples from 222 sporadic CRC patients.
- Detection of K-ras codon 12 and 13 activating mutations using molecular techniques.
- Assessment of RASSF1A promoter hypermethylation via methylation-specific assays.
Main Results:
- K-ras mutations were found in 39% of CRCs, while RASSF1A methylation was observed in 20%.
- K-ras mutations alone occurred in 34% of cases, and RASSF1A methylation with wild-type K-ras in 15%.
- The majority of CRCs with K-ras mutations lacked RASSF1A methylation (P=0.023), indicating these alterations predominantly occur in distinct CRC subsets.
Conclusions:
- Both K-ras mutations and RASSF1A promoter hypermethylation are significant alterations in sporadic CRC.
- These genetic and epigenetic events appear to be largely mutually exclusive, suggesting distinct molecular subtypes of CRC.
- Understanding these distinct pathways can inform targeted therapeutic strategies for colorectal cancer.